drugset
drugset / Trial / NCT00646958

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

NCT00646958 ↗

Phase 2 Completed 150 enrolled Melinta Therapeutics, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of RX-1741, an oxazolidinone, versus linezolid, another oxazolidinone, in the treatment of uncomplicated skin and skin structure infections

Timeline

Start
2007-12
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linezolid Other / unclassified 600 mg Oral
Subject Radezolid Small molecule 450 mg Oral

Indications

abscess skin disease caused by bacterial infection staphylococcal infection streptococcal infection